ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
April 15 2021 - 6:30PM
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage
biotechnology company focused on the discovery and development of
direct lytic agents (DLAs), including lysins and amurin peptides,
as new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that Cara Cassino,
MD, Chief Medical Officer and Executive Vice President of Research,
will virtually present the Company’s anti-infective portfolio and
platform technology of DLAs in the session on “Advancing Clinical
Superiority of Anti-Infectives to Drive Commercial Success.”
Dr. Cassino’s presentation will focus on the
powerful antimicrobial attributes of DLAs which underpin the
potential for superior clinical outcomes for serious,
life-threatening, and critically underserved infections and the
Company’s novel development pathway expected to demonstrate
clinical superiority.
Presentation Details:
Presentation Title: Direct Lytic Agents (DLAs):
New Medical Modalities for Life-Threatening, Drug-Resistant
InfectionsTime and Date: Thursday, April 22,
2021, 9:00 a.m. EDT
Q&A/Discussion Follows at 9:50 a.m. EDT
About ContraFect
ContraFect is a biotechnology company focused on
the discovery and development of DLAs, including lysins and amurin
peptides, as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our platform of DLAs, which include lysins and amurin
peptides. Lysins are a new class of DLAs which are recombinantly
produced antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are a novel class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including P. aeruginosa, Acinetobacter baumannii, and
Enterobacter species. We believe that the properties of our lysins
and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as MRSA and P. aeruginosa,
which can cause serious infections such as bacteremia, pneumonia
and osteomyelitis. We have completed a Phase 2 clinical trial for
the treatment of Staph aureus bacteremia, including endocarditis,
with our lead lysin candidate, exebacase, which is the first lysin
to enter clinical studies in the U.S. Exebacase, currently being
studied in a pivotal Phase 3 clinical study, was granted
Breakthrough Therapy designation by the FDA for the treatment of
MRSA bloodstream infections, including right-sided endocarditis,
when used in addition to SOC anti-staphylococcal antibiotics in
adult patients.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding: Dr. Cassino’s
presentation, ContraFect’s ability to discover and develop DLAs as
new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, whether ContraFect will address
life-threatening infections using its DLA platform, whether lysins
are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, whether amurins are a
novel class of DLAs which exhibit broad-spectrum activity against a
wide range of antibiotic-resistant Gram-negative pathogens, and
whether the properties of ContraFect’s lysins and amurins will make
them suitable for targeting antibiotic-resistant organisms, such as
MRSA and P. aeruginosa. Forward-looking statements are statements
that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including the occurrence of any adverse events related to
the discovery, development and commercialization of ContraFect’s
product candidates such as unfavorable clinical trial results,
insufficient supplies of drug products, the lack of regulatory
approval, or the unsuccessful attainment or maintenance of patent
protection and other important risks detailed under the caption
“Risk Factors” in ContraFect's filings with the Securities and
Exchange Commission. Actual results may differ from those set forth
in the forward-looking statements. Important factors that could
cause actual results to differ include, among others, our ability
to develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts
Michael MessingerContraFect
Corporationmmessinger@contrafect.com
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallinvestorrelations.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024